Analyst Price Targets — ALEC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 4, 2026 12:16 pm | — | Morgan Stanley | $2.00 | $2.45 | TheFly | Alector price target raised to $2 from 90c at Morgan Stanley |
| October 22, 2025 1:05 pm | — | H.C. Wainwright | $5.00 | $3.21 | TheFly | Alector price target lowered to $5 from $10 at H.C. Wainwright |
| October 22, 2025 8:38 am | — | Mizuho Securities | $1.50 | $3.21 | TheFly | Alector downgraded to Neutral from Outperform at Mizuho |
| November 19, 2024 9:07 pm | Corinne Jenkins | Goldman Sachs | $4.00 | $5.08 | StreetInsider | Goldman Sachs Reiterates Sell Rating on Alector Inc. (ALEC) |
Latest News for ALEC
Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.3 per share a year ago.
Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's disease (AD). Continued progress across AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)).
Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALEC.
U.S. House Trading
No House trades found for ALEC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.